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Abstract 22 
Biospectroscopy has the potential to investigate and characterise biological samples and could, 23 
therefore, be utilised to diagnose various diseases in a clinical environment. An important 24 
consideration in spectrochemical studies is the cost-effectiveness of the substrate used to 25 
support the sample, as high expense would limit their translation into clinic. In this paper, the 26 
performance of low-cost aluminium (Al) foil substrates was compared with the commonly used 27 
low-emissivity (low-E) slides. Attenuated total reflection-Fourier transform infrared (ATR-28 
FTIR) spectroscopy was used to analyse blood plasma and serum samples from women with 29 
endometrial cancer and healthy controls. The two populations were differentiated using 30 
principal component analysis with support vector machines (PCA-SVM) with 100% sensitivity 31 
in plasma samples (endometrial cancer=70; healthy controls=15) using both Al foil and low-E 32 
slides as substrates. The same sensitivity results (100%) were achieved for serum samples 33 
(endometrial cancer=60; healthy controls=15). Specificity was found higher using Al foil 34 
(90%) in comparison to low-E slides (85%) and lower using Al foil (70%) in comparison to 35 
low-E slides in serum samples. The establishment of Al foil as low-cost and highly-performing 36 
substrate would pave the way for large-scale, multi-centre studies and potentially for routine 37 
clinical use. 38 
 39 
 40 
 41 
 42 
 43 
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Introduction  44 
Vibrational spectroscopy is increasingly utilised in biomedical research as a valuable tool in 45 
disease investigation. Allowing the analysis of a variety of biological samples, such as cells, 46 
tissues and biofluids, this spectrochemical analysis has a bright future ahead, not only in 47 
scientific/laboratory research but also in clinical practice. The key factor that renders this 48 
analytical method a perfect diagnostic tool, in comparison to other molecular methods, is its 49 
non-destructive, cost-effective and label-free nature. Over the years, infrared (IR) and Raman 50 
spectroscopic techniques have been employed to study a number of different diseases like 51 
cancer, neurological diseases, prenatal disorders and many others 1-10. Within the field of 52 
disease investigation, spectroscopy has the potential to diagnose and monitor a disease, while 53 
at the same time assessment of surgical margins of a tumour or determination of the subtype 54 
of a disease is also feasible. 55 
 Most spectroscopic studies so far, with only a few exceptions 8, 10, 11, have included a 56 
limited number of subjects which appears to be an important limitation for the establishment 57 
of the method and its migration into clinics 12-14. Standardisation and validation of methods 58 
should be performed in large clinical trials for more robust and trustworthy results. A further 59 
issue that limits the ability for clinical implementation relates to experimental methodology. 60 
Specifically, inconsistencies in the pre-analytical stages of sample collection and preparation 61 
to spectral collection and data analysis. A fundamental factor of the analytical procedure is the 62 
use of the correct substrate in order to avoid non-biological interference from the substrate in 63 
use. Unfortunately, the majority of the available, “featureless” substrates are high-cost 15, 16, 64 
something which prevents their use in large scale studies and routine analysis. Previous studies 65 
have even developed data correction algorithms to remove the substrate’s signal after the 66 
collection of the raw spectra 16-18. 67 
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 Different types of substrates are selected depending on the spectroscopic technique used 68 
each time (e.g., IR or Raman spectroscopy), as well as on the chosen sampling mode [e.g., 69 
transmission IR, transflection IR or attenuated total reflection (ATR)]. Namely, some of the 70 
substrates that have been used for IR and Raman spectroscopy over the years include barium 71 
fluoride (BaF2), calcium fluoride (CaF2), zinc selenide (ZnSe), gold-coated (Au), silver or 72 
silver-coated (Ag), fused silica (SiO2) and low-emissivity (low-E) slides 
19, 20. However, due to 73 
their expense, efforts are being made to introduce novel, low-cost substrates that would 74 
facilitate the analysis of hundreds, even thousands, of samples cost-effectively. Glass substrates 75 
are routinely used in medical laboratories and hospitals for preparation of analysis of various 76 
types of biological samples; however, glass has been found unsuitable for spectroscopy as it 77 
generates background signal and distorts the biological information coming from the samples 78 
19. Therefore, an ideal approach would be to take advantage of the extremely cost-effective 79 
glass slides by covering them with a metallic surface that would eliminate any background 80 
noise. Previous proof-of-concept studies have been conducted showing aluminium (Al) foil’s 81 
potential as a suitable substrate 11, 16, 21. A robust and inexpensive substrate for both IR and 82 
Raman spectroscopic methods would be extremely beneficial. However, there has been no 83 
conclusive study comparing its effect on diagnostic accuracy with other, widely used 84 
substrates. 85 
 In this study, we used ATR-FTIR spectroscopy to explore whether Al foil could be an 86 
appropriate substrate for spectroscopic investigations. ATR-FTIR uses an internal reflection 87 
element (IRE) with a high refractive index to direct the beam to the sample; an evanescent 88 
wave is created, penetrating the sample by a few microns in order to derive its chemical 89 
information 22. A commonly used substrate for ATR-FTIR measurements is the low-E slide, 90 
which has been effectively used in numerous biological studies in the past 23-25.  Therefore, we 91 
compared our results from the low-E slides with those from Al foil slides to assess the 92 
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performance of the latter with regard to the diagnostic accuracy. For the purpose of this piece 93 
of work, we analysed blood samples from women with endometrial cancer, as well as from 94 
benign cases used as controls. Endometrial cancer develops in the endometrium (i.e., inner 95 
lining of the uterus) and is the fourth most common gynaecological cancer in the developing 96 
world, with an increasing incidence in postmenopausal women; in 2012 alone, 319,000 new 97 
cases were diagnosed worldwide 26. Although symptoms of endometrial cancer develop 98 
relatively early, which allows “timely” diagnosis and early intervention, a more objective, less 99 
expensive and non-invasive method of diagnosing this type of cancer is highly desirable and 100 
clinically indicated. Currently, a diagnosis is based on microscopic histological examination of 101 
endometrial tissue, which is dependent on subjective interpretation, therefore allowing human 102 
error. 103 
Materials and Methods 104 
Blood plasma and serum analysis 105 
The collection of all samples for this study was approved by the institutional review board at 106 
Imperial College Healthcare NHS Trust (tissue bank sub-collection number GYN/HG/13-020). 107 
All patients provided informed consent for use of their samples in this study. This study 108 
included age-matched cohorts; plasma samples were available for 70 endometrial cancer 109 
patients and 15 non-cancer individuals used as controls; serum samples were available for 60 110 
endometrial cancer patients and 15 controls. At time of diagnosis, patients were not receiving 111 
any medications such as Tamoxifen treatments which might affect the outcomes. Also women 112 
who had hyperplasia or hypertension have been excluded. Both blood plasma and serum 113 
samples were collected and stored at -80°C until analysis; prior to spectroscopic interrogation, 114 
the samples were left to defrost at room temperature before 50 μL of each were deposited on a 115 
substrate and left to air-dry for approximately 30 min. All of the samples were analysed in 116 
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duplicates using two different substrates: the IR-reflective glass slides (MirrIR Low-E slides, 117 
Kevley Technologies, USA) and cheap, microscope glass slides covered with Al foil. The latter 118 
were carefully flattened with the shiny side of the foil being exposed to achieve a greater level 119 
of reflectivity. Covering the slide with Al foil required ~30-45 seconds with one slide taking 120 
up to 3 different samples, rendering the slide preparation time insignificant. 121 
Spectrochemical Analysis 122 
All blood samples were analysed using a Tensor 27 FTIR spectrometer with Helios ATR 123 
attachment (Bruker Optics Ltd, Coventry, UK). The sampling area, defined by the internal 124 
reflection element (IRE), which was a diamond crystal, was approximately 250 μm × 250 μm. 125 
The slide with the sample is placed onto a moving platform with the sample facing up; the 126 
platform is then moved upward to achieve good contact with the diamond crystal. Spectral 127 
resolution was 8 cm-1 with two times zero-filling, giving a data-spacing of 4 cm-1 over the range 128 
4000-400 cm-1; 32 co-additions and a mirror velocity of 2.2 kHz were used for optimum signal 129 
to noise ratio. A CCTV camera attachment was used to locate the area of interest and spectra 130 
were acquired from ten different locations to minimize bias. Also, in order to take into 131 
consideration the natural phenomenon of “coffee ring” effect, spectra were mainly collected 132 
from the periphery of each drop where the absorbance intensity was higher, as important 133 
components, such as proteins and nucleic acids, migrate towards the edge of the drop after 134 
drying 27. The ATR crystal was cleaned with distilled water before moving to a different sample 135 
and a background spectrum was acquired to take into account any atmospheric changes. 136 
Spectral data handling and analysis 137 
All spectral information was converted to suitable files (.txt) before input to MATLAB 138 
(Mathworks, Natick, USA). Pre-processing and computational analysis of the data was 139 
performed using PLS Toolbox version 7.9.3 (Eigenvector Research, Inc., Manson, USA) and 140 
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an in-house developed IRootLab toolbox (http://trevisanj.github.io/irootlab/). Pre-processing 141 
of the acquired spectra is an essential step of all spectroscopic experiments and is used to 142 
correct problems associated with spectral acquisition, instrumentation or even sample handling 143 
before further multivariate analysis 28. In this study, spectra were cut at the biochemical 144 
fingerprint region (1800-900 cm-1), rubberband baseline corrected and vector normalised. 145 
The samples were divided into training (~70%), validation (~15%) and test (~15%) sets 146 
on a patient basis before chemometric analysis, using the Kennard-Stone sample selection 147 
algorithm 29; all spectra collected for each individual were used for model construction. In total, 148 
60 samples were used for training (n = 600 spectra), 12 for validation (n = 120 spectra) and 13 149 
for test (n = 130 spectra) with plasma samples; and 53 for training (n = 530 spectra), 11 for 150 
validation (n = 110 spectra) and 11 for test (n = 110 spectra) with serum samples. The training 151 
set was used for model construction, the validation set for optimization of the number of 152 
principal components and latent variables used, and the test set for final model evaluation. 153 
Cross-validation venetian blinds (10 splits with 1 sample per split) was used for optimization 154 
of support vector machines (SVM) parameters (cost, epsilon, gamma and number of support 155 
vectors) in principal component analysis with support vector machines (PCA-SVM). 156 
For the classification of endometrial cancer and non-cancer cases a number of 157 
chemometric techniques was used, such as partial least squares discriminant analysis (PLS-158 
DA); and principal component analysis followed by linear discriminant analysis (PCA-LDA), 159 
quadratic discriminant analysis (PCA-QDA) and support vector machines (PCA-SVM). 160 
PLS-DA is one of the most known chemometric technique of supervised classification. 161 
It is based on a linear classification model for which the classification criterion is obtained by 162 
partial least squares (PLS) analysis 30. For this, PLS is applied to the data reducing the original 163 
variables (e.g., wavenumbers) to a few number of latent variables (LVs) in an interactive 164 
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process, in which the category variables for each class in the training set (e.g., ±1) is used to 165 
optimise the model. A straight line that divides the classes’ regions is then found 31. 166 
Similarly to PLS, PCA also reduces the original data into a few set of variables called 167 
principal components (PCs). These variables are orthogonal to each other and account most of 168 
the explained variance from the original data set. They are composed of scores and loadings 169 
that are used to identify similarities/dissimilarities among the samples and the weight that each 170 
variable contributes for the PCA model, respectively 32. However, differently from PLS, the 171 
category variables are not used for this reduction. To perform a supervised classification model, 172 
the PCA scores are employed as input variables for discriminant algorithms. This procedure 173 
avoids collinearity problems and also speeds up computational analysis. 174 
LDA and QDA are discriminant algorithms that create a classification rule between the 175 
classes based on a Mahalanobis distance. The main difference between these techniques is that 176 
LDA uses a pooled covariance matrix to calculate the discriminant function between the 177 
classes, whereas QDA uses the variance-covariance matrix of each class separately 33. 178 
Therefore, QDA usually achieves better performance than LDA when analysing complex data 179 
sets where the variance structures between the classes are very different. The LDA (𝐿𝑖𝑘) and 180 
QDA (𝑄𝑖𝑘) classification scores are calculated following the equations 
34: 181 
𝐿𝑖𝑘 = (𝐱𝑖 − ?̅?𝑘)
T∑pooled
−1 (𝐱𝑖 − ?̅?𝑘) − 2 log𝑒 𝜋𝑘       (1) 182 
𝑄𝑖𝑘 = (𝐱𝑖 − ?̅?𝑘)
T∑𝑘
−1(𝐱𝑖 − ?̅?𝑘) + log𝑒|∑𝑘| − 2 log𝑒 𝜋𝑘      (2) 183 
in which 𝐱𝑖 is the vector containing the classification variables for sample 𝑖 (e.g., PCA scores 184 
for A components); ?̅?𝑘 is the mean vector of class k; ∑𝑘  is the variance-covariance matrix of 185 
class k; ∑pooled  is the pooled covariance matrix; and 𝜋𝑘 is the prior probability of class k. 186 
These last three terms are calculated by 34:  187 
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∑𝑘 =
1
𝑛𝑘−1
∑ (𝐱𝑖 − ?̅?𝑘)
𝑛𝑘
𝑖=1 (𝐱𝑖 − ?̅?𝑘)
T        (3) 188 
∑pooled =
1
𝑛
∑ 𝑛𝑘∑𝑘 
𝐾
𝑘=1           (4) 189 
𝜋𝑘 =
𝑛𝑘
𝑛
            (5) 190 
where 𝑛𝑘 is the number of samples of class k; 𝑛 is the total number of samples in the training 191 
set; and 𝐾 is the number of classes. 192 
 On the other hand, SVM is a technique that classifies data sets in a completely non-193 
linear fashion. For this, SMVs classifiers work by finding a classification hyperplane that 194 
separates the data clusters providing the largest margin of separation 35. During model 195 
construction, the data is transformed into a different feature space by means of a kernel function 196 
that is responsible for the SVM classification ability 33. The most common kernel function is 197 
the radial basis function (RBF). The SVM classifier takes the form of 36: 198 
𝑓(𝑥) = sign(∑ 𝛼𝑖𝑦𝑖𝐾(𝐱𝑖 , 𝐳𝑗) + 𝑏
𝑁𝑆𝑉
𝑖=1 )        (6) 199 
where 𝑁𝑆𝑉 is the number of support vectors; 𝛼𝑖 is the Lagrange multiplier; 𝑦𝑖 is the class 200 
membership (e.g., ±1); 𝑏 is the bias parameter; and 𝐾(𝐱𝑖, 𝐳𝑗) is the RBF kernel function, 201 
calculated by: 202 
𝐾(𝐱𝑖, 𝐳𝑗) = exp (−𝛾‖𝐱𝑖 − 𝐳𝑗‖
2
)         (7) 203 
in which 𝐱𝑖 and 𝐳𝑗  are samples measurement vectors; and 𝛾 is the parameter that determines 204 
the RBF width. 205 
Results and Discussion 206 
By employing the above-mentioned multivariate techniques (PCA-LDA, PLS-DA, PCA-QDA 207 
and PCA-SVM), it was demonstrated that some provided superior performance than others. 208 
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The techniques were very different from each other and were used following a parsimonious 209 
order (PCA-LDA < PLS-DA < PCA-QDA < PCA-SVM). It is natural to expect an 210 
improvement of the results when more robust algorithms are applied, as the classification 211 
methods varied from a linear (PCA-LDA and PLS-DA) to a completely non-linear 212 
classification algorithm (PCA-SVM). Analysis of the plasma samples deposited on Al foil 213 
showed classification to be: 68% sensitivity and 70% specificity (68% accuracy) after PLS-214 
DA; 47% sensitivity and 75% specificity after PCA-LDA (51% accuracy); 83% sensitivity and 215 
45% specificity after PCA-QDA (78% accuracy); 100% sensitivity and 90% specificity (98% 216 
accuracy) after PCA-SVM. For plasma samples that were deposited on low-E slides the results 217 
were: 65% sensitivity and 65% specificity (65% accuracy) after PLS-DA; 46% sensitivity and 218 
85% specificity (52% accuracy) after PCA-LDA; 96% sensitivity and 15% specificity (84% 219 
accuracy) after PCA-QDA; 100% sensitivity and 85% specificity (98% accuracy) after PCA-220 
SVM (Table 1). All PCA-based models for plasma samples were built with 10 PCs, accounting 221 
99.11% and 96.84% of explained variance for Al and low-E substrates, respectively. PLS-DA 222 
was built with 10 LVs, accounting 98.97% and 95.28% of explained variance for Al and low-223 
E substrates, respectively. 224 
After applying classification algorithms for the blood serum samples, the results using 225 
Al foil as a substrate were: 82% sensitivity and 75% specificity (81% accuracy) after PLS-DA; 226 
90% sensitivity and 40% specificity (81% accuracy) after PCA-LDA; 94% sensitivity and 50% 227 
specificity (86% accuracy) after PCA-QDA; 100% sensitivity and 70% specificity (94% 228 
accuracy) after PCA-SVM. When using serum samples on low-E slides the results were: 78% 229 
sensitivity and 90% specificity (80% accuracy) after PLS-DA; 63% sensitivity and 50% 230 
specificity (61% accuracy) after PCA-LDA; 97% sensitivity and 20% specificity (83% 231 
accuracy) after PCA-QDA; 100% sensitivity and 75% specificity (95% accuracy) after PCA-232 
SVM (Table 2). All PCA-based models for serum samples were built with 10 PCs, accounting 233 
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for 98.78% and 97.50% of explained variance for Al and low-E substrates, respectively. PLS-234 
DA was built with 10 LVs, accounting for 98.43% and 90.24% of explained variance for Al 235 
and low-E substrates, respectively. 236 
Overall, PCA-SVM was found to provide optimal results for both plasma and serum 237 
samples regardless of the substrate that was used (Fig. 1 and 2). This was due to the fact that 238 
PCA-SVM can create a more complex decision boundary between the classes, classifying even 239 
non-linearly separable data 33, 35. In addition, SVM creates large margins of separation between 240 
the classes, which provides more stability to the classifier. In this sense, small disturbances or 241 
noises do not cause misclassification 35. Standard deviation (SD) was higher for Al foil in 242 
comparison to low-E slides (Fig. 1 and 2). This improved the Al foil classification models as 243 
more sources of variation were contemplated during model construction, thus creating well-244 
distributed boundary functions and increasing the robustness of the classification. The SD in 245 
the training set decreases the degree of overfitting and provides better predictive capacity 37. 246 
The PCA-SVM cost function and optimization to estimate RBF parameters are shown in Fig. 247 
3, where the red ‘X’ mark represents the optimal value. This optimization was performed in 248 
order to avoid overfitting and to ensure classification stability. Fig. 4 shows the reference and 249 
predicted class labels (1 for control; and 2 for cancer) using PCA-SVM with the samples from 250 
the test set; if the yellow (predicted) and blue (reference) lines are superposed, then the values 251 
are equal (i.e., no misclassification). For all substrates and type of samples (plasma and serum), 252 
there was no misclassification in the cancer set, reflecting the 100% sensitivity of PCA-SVM 253 
models. A degree of misclassification was observed in the control set, particularly when using 254 
serum samples. More specifically, specificity was higher in Al foil (90%) in contrast to low-E 255 
(85%); this has provided the slightly higher accuracy in Al foil (98.5%) in contrast to low-E 256 
(97.7%), in the plasma dataset. This can be seen in Fig. 4A and 4B as there are two and three 257 
misclassified spectra, respectively (“continuous” peaks represent more than one spectrum). The 258 
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specificity differed slightly in the serum dataset too, when Al foil (70%) and low-E (75%) were 259 
used. This contributed to the slightly lower accuracy in Al foil (94.5%) in contrast to low-E 260 
(95.5%). In this case, there were six misclassified spectra for Al foil and five for low-E slides. 261 
Although both PCA-LDA and PCA-QDA were regularized to correct classes having different 262 
sizes (prior probability term in eq. 1 and 2), the number of errors is larger on the smaller class 263 
(healthy control) due to the influence of the unequal class sizes to the classifiers. To summarise, 264 
Al foil has been seen to perform better than low-E in the plasma dataset, while in the serum 265 
dataset it achieved slightly lower specificity, but still high enough and comparable to low-E. 266 
PCA-SVM models (Fig. 5) have different loadings profiles according to the type of 267 
sample and substrate. The loadings are dependent on the nature of the dataset used for the PCA 268 
model and they can differ depending on the input. Even though the same sample type is used, 269 
the change of the substrate has subsequently changed the spectral profile as well. Any variation 270 
above the instrumental noise can cause variation in the loading profiles. For instance, 271 
differentiation was also observed at specific spectral peaks between Al foil and low-E 272 
substrates (Fig. S1). Even though some spectral regions were visually similar, the reasoning of 273 
using multivariate analysis is to overcome visual interpretation which can be inaccurate. 274 
Therefore, a statistical t-test (95% confidence level) has been performed to calculate p-values 275 
for each spectral point between Al foil and low-E as well as between plasma and serum. The 276 
results showed that many wavenumbers were statistically significant (p <0.05, 95% confidence 277 
level) irrespectively of the visual similarities (Fig. S2). Additionally, the fact that PC1 278 
accounted for low values of explained variance (70.09% for plasma-Al; 38.98% for plasma 279 
low-E; 69.48% for serum-Al; and 28.69% for serum low-E) due to the high complexity of the 280 
biological dataset, makes the loadings interpretation even harder. 281 
Using aluminium as substrate, larger coefficients were found between ~1000-1150 cm-282 
1 for both plasma and serum samples, indicating possible glycogen and phosphate absorptions; 283 
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between ~1400-1480 cm-1, indicating possible stretching vibrations of COO- groups in fatty 284 
acids and amino acids; at ~1504 cm-1 for serum, signalling amide II absorption; and at ~1744 285 
cm-1 for plasma, indicating C=O stretching of lipids 38. Using low-E slides as substrate for 286 
plasma samples, larger coefficients were found at ~1628 cm-1 (amide I), ~1655 cm-1 (amide I) 287 
and ~1744 cm-1 (C=O stretching of lipids); whereas for serum samples, the coefficients were 288 
greater at ~1504 cm-1 (amide II), ~1620 cm-1 (base carbonyl stretching and ring breathing mode 289 
in nucleic acids) and 1655 cm-1 (amide I) 38. Such absorptions are known for signalling 290 
biological changes using mid-IR spectroscopy 19. 291 
The classification accuracies achieved for the segregation between endometrial cancer 292 
patients and controls are remarkably high (~95-98%), suggesting that blood-based ATR-FTIR 293 
spectroscopy could potentially be an accurate and objective diagnostic tool for endometrial 294 
cancer. Investigation of a panel of multiple biomolecules could be the reason for the achieved 295 
accuracies. Several molecular biomarkers have been suggested over the years, such as 296 
carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cancer antigen 15-3 (CA15-3), 297 
immunosuppressive acidic protein (IAP), human epididymis protein-4 (HE4), apolipoprotein-298 
1 (ApoA-1), prealbumin (TTR) and transferrin (TF); a combination of CA125 and HE4 has 299 
also been implied to improve diagnosis and classification of the disease 39-42. However, the 300 
resulting sensitivities and specificities of the above-mentioned biomarkers are low, rendering 301 
them clinically unusable. Therefore, spectroscopic methods are ideal, as they can 302 
simultaneously extract information from a range of molecules. Another possible rationale 303 
behind the diagnostic results could be the existence of circulating tumour DNA (ctDNA) 304 
fragments in the bloodstream of cancer patients, which would make them distinct from the 305 
normal population 43, 44. Nowadays, ctDNA is increasingly investigated and is considered to be 306 
useful as a biomarker for malignancy cases 45. Nevertheless, for an accurate and specific 307 
biomarker detection, vibrational spectroscopy would need to be complemented with other 308 
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techniques as well, or maybe make use of labels or antibodies that would be molecule specific. 309 
IR spectroscopy alone indicates some molecular fragments which are indicative of 310 
biomolecules, such as proteins, lipids or carbohydrates. However, each spectral peak may 311 
‘hide’ more than one molecules and thus, it is not preferred to assign specific biomarkers to 312 
specific peaks. 313 
In this study, plasma samples resulted in slightly higher diagnostic accuracies (~98%) 314 
in contrast to serum samples (~95%). Current studies are unclear on whether serum or plasma 315 
is a better source for ctDNA 44. However, plasma has been previously found superior and the 316 
specificity obtained using serum has been related to a higher concentration of normal cell-free 317 
DNA (cfDNA), produced by the lysis of white blood cells during clotting 46, 47. This could 318 
potentially justify the lower classification rates found when using serum. 319 
Careful consideration of the substrate, onto which the biological sample is placed, is 320 
critical in order to collect reproducible and high-quality spectra. When comparing the 321 
classification results coming from Al foil and low-E slides (Fig. 1 and 2), it is clear that Al foil 322 
not only achieved equally high results with low-E but, in the plasma dataset, it even provided 323 
slightly higher sensitivities and specificities (Fig. 1). Previous work has indicated that Al foil 324 
generates no background noise, leaving the quality of the biological spectra unaffected; our 325 
study used a larger number of subjects, which was needed to verify these preliminary results 326 
and also study the impact on the sensitivity and specificity. Studies have also demonstrated the 327 
enhancement of the IR signal in ATR mode when the sample is deposited onto metal surfaces 328 
creating a similar effect to surface enhanced Raman spectroscopy (SERS), which has been 329 
given the name surface enhanced IR absorption spectroscopy (SEIRAS). Molecules on metal 330 
surfaces show 10-100 times stronger signal that without the metal 48-51 and on the basis of this 331 
we have hypothesized that Al foil slides may also promote this effect. However, this requires 332 
further and more detailed investigation that will be the focus of a future study. The economic 333 
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cost of low-E slides has been estimated before and is not extremely high, especially when 334 
compared with substrates like CaF2 and Au-coated slides 
21. Nonetheless, when it becomes a 335 
matter of routine use, in a clinical setting for instance, the annual cost becomes considerably 336 
high and this could render biospectroscopy prohibitive for translation into clinical practice. The 337 
fact that Al foil slides are suitable for both IR and Raman studies is also an important advantage 338 
as it would ease clinical implementation.  The results of our study have shown that Al foil 339 
slides could make an ideal, cost-effective substrate for biomedical studies employing 340 
vibrational spectroscopy. 341 
Conclusion 342 
To summarise, biospectroscopy could potentially be used as a screening tool for endometrial 343 
cancer in postmenopausal women as it provides exceptionally high sensitivities and 344 
specificities with a simple blood test. This could automatically enable a large number of women 345 
to be assessed on a daily basis. Using disposable, low-cost and, at the same time, high-346 
performance substrates would allow for universal studies with thousands of participants; this 347 
would probably also generate an interest for multi-centre studies which could further validate 348 
the pre-analytical, analytical and post-analytical phases of biospectroscopy. 349 
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Figures 358 
 359 
Figure 1: Pre-processed spectra of plasma comparing endometrial cancer (n=70) with 360 
controls (n=15). (A) Endometrial cancer versus healthy controls; samples were analysed on 361 
aluminium (Al) foil. Sensitivity and specificity were 100% and 90%, respectively. (B) 362 
Endometrial cancer versus healthy controls; samples analysed on low-E slides. Sensitivity and 363 
specificity were 100% and 85%, respectively.  364 
 365 
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 366 
Figure 2: Pre-processed spectra of serum comparing endometrial cancer (n=60) with 367 
controls (n=15). (A) Endometrial cancer versus healthy controls; samples were analysed on 368 
aluminium (Al) foil. Sensitivity and specificity were 100% and 70%, respectively. (B) 369 
Endometrial cancer versus healthy controls; samples analysed on low-E slides. Sensitivity and 370 
specificity were 100% and 75%, respectively.  371 
 372 
18 
 
 373 
Figure 3: PCA-SVM cost function and radial basis function (RBF) parameter 374 
optimization. (A) Plasma samples with aluminium (Al) foil as a substrate. (B) Plasma samples 375 
with low-E slides as a substrate. (C) Serum samples with aluminium (Al) foil as substrate. (D) 376 
Serum samples with low-E slides as substrate. Gamma: RBF parameter (𝛾). Colour bar: 377 
misclassification rate using cross-validation. 378 
 379 
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 380 
Figure 4: Reference and predicted class labels using PCA-SVM in the test set. (A) Plasma 381 
samples with aluminium (Al) foil as a substrate; sensitivity was 100% and specificity 90% (two 382 
misclassified spectra). (B) Plasma samples with low-E slides as a substrate; 100% sensitivity 383 
and 85% specificity (three misclassified spectra). (C) Serum samples with aluminium (Al) foil 384 
as substrate; 100% sensitivity and 70% specificity (six misclassified spectra). (D) Serum 385 
samples with low-E slides as substrate; 100% sensitivity and 75% specificity (five 386 
misclassified spectra). Class 1 = control; and class 2 = cancer. 387 
Plasma: Al Plasma: Low-E
Serum: Al Serum: Low-E
A B
C D
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 388 
Figure 5: Loading plots generated after PCA analysis. (A) Loadings on PC1, PC2 for 389 
plasma samples deposited on aluminium (Al) foil slides. (B) Loadings on PC1, PC2 for plasma 390 
samples deposited on low-E slides. (C) Loadings on PC1, PC2 for serum samples deposited on 391 
aluminium (Al) foil slides. (D) Loadings on PC1, PC2 for serum samples deposited on low-E 392 
slides.  393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
 404 
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Tables 405 
 406 
Table 1: Classification algorithms applied after the analysis of blood plasma samples. 407 
Results for both substrates, aluminium foil and low-E slide, are shown below.   408 
Correct classification rate (%): 409 
 Training (%) Validation (%) Test (%) 
Aluminium foil    
PLS-DA 69.1 64.5 68.5 
PCA-LDA 67.8 65.0 51.5 
PCA-QDA 85.2 80.0 77.7 
PCA-SVM 99.0 93.3 98.5 
Low-E    
PLS-DA 71.1 71.8 65.4 
PCA-LDA 62.7 54.2 52.3 
PCA-QDA 85.2 82.5 83.8 
PCA-SVM 99.8 97.5 97.7 
 410 
Quality parameters (%): 411 
 Accuracy (%) Sensitivity (%) Specificity (%) 
Aluminium foil    
PLS-DA 68.5 68.2 70.0 
PCA-LDA 51.5 47.3 75.0 
PCA-QDA 77.7 83.6 45.0 
PCA-SVM 98.5 100 90.0 
Low-E    
PLS-DA 65.4 65.5 65.0 
PCA-LDA 52.3 46.4 85.0 
PCA-QDA 83.8 96.4 15.0 
PCA-SVM 97.7 100 85.0 
 412 
  413 
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Table 2: Classification algorithms applied after the analysis of blood serum samples. 414 
Results for both substrates, aluminium foil and low-E slide, are shown below.   415 
SERUM 416 
Correct classification rate (%): 417 
 Training (%) Validation (%) Test (%) 
Aluminium foil    
PLS-DA 80.0 79.1 80.9 
PCA-LDA 72.1 79.1 80.9 
PCA-QDA 84.3 79.1 86.4 
PCA-SVM 98.3 93.6 94.5 
Low-E    
PLS-DA 85.7 71.8 80.0 
PCA-LDA 70.2 65.5 60.9 
PCA-QDA 84.2 88.2 82.7 
PCA-SVM 99.1 98.2 95.5 
 418 
Quality parameters (%): 419 
 Accuracy (%) Sensitivity (%) Specificity (%) 
Aluminium foil    
PLS-DA 80.9 82.2 75.0 
PCA-LDA 80.9 90.0 40.0 
PCA-QDA 86.4 94.4 50.0 
PCA-SVM 94.5 100 70.0 
Low-E    
PLS-DA 80.0 77.8 90.0 
PCA-LDA 60.9 63.3 50.0 
PCA-QDA 82.7 96.7 20.0 
PCA-SVM 95.5 100 75.0 
 420 
 421 
 422 
 423 
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